Company news
Catalyst Pharmaceuticals, Inc. news in 2022
Catalyst Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
December 18, 2022
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
November 8, 2022
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
November 6, 2022
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
October 24, 2022
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
September 28, 2022
Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 8, 2022
Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference
August 23, 2022
Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update
August 8, 2022
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
July 25, 2022
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
July 11, 2022
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
May 16, 2022
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
May 9, 2022
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
April 24, 2022
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 15, 2022
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
March 10, 2022
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
March 7, 2022
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
March 2, 2022
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
March 1, 2022
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
February 23, 2022
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
February 16, 2022
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
February 6, 2022
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
February 2, 2022
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst
January 27, 2022
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
January 9, 2022
Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
January 3, 2022
Calls in 2022
- Catalyst Pharmaceuticals (NASDAQ:CPRX) Q3 2022 Earnings Call
Nov 10, 2022
Transcript - Catalyst Pharmaceuticals (NASDAQ:CPRX) Q2 2022 Earnings Call
Aug 10, 2022
Transcript - Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 2022 Earnings Call
May 11, 2022
Transcript - Catalyst Pharmaceuticals (NASDAQ:CPRX) Q4 2021 Earnings Call
Mar 17, 2022
Transcript